HC Wainwright Forecasts OptiNose FY2029 Earnings

OptiNose, Inc. (NASDAQ:OPTN) – Research analysts at HC Wainwright issued their FY2029 EPS estimates for OptiNose in a note issued to investors on Friday, January 3rd. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of $1.41 per share for the year. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for OptiNose’s current full-year earnings is ($0.20) per share.

Separately, Piper Sandler decreased their price objective on OptiNose from $45.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th.

OptiNose Stock Performance

Shares of NASDAQ OPTN opened at $6.50 on Monday. The firm’s 50 day moving average price is $7.81 and its 200 day moving average price is $11.82. The firm has a market cap of $65.39 million, a P/E ratio of -23.21 and a beta of -0.15. OptiNose has a 1 year low of $4.82 and a 1 year high of $31.50.

Institutional Investors Weigh In On OptiNose

Several hedge funds have recently modified their holdings of OPTN. Geode Capital Management LLC raised its stake in OptiNose by 33.7% during the third quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company’s stock worth $870,000 after purchasing an additional 326,918 shares during the period. State Street Corp increased its holdings in shares of OptiNose by 14.2% during the 3rd quarter. State Street Corp now owns 341,303 shares of the company’s stock worth $229,000 after buying an additional 42,500 shares during the last quarter. Stonepine Capital Management LLC raised its position in shares of OptiNose by 142.1% in the 3rd quarter. Stonepine Capital Management LLC now owns 5,688,590 shares of the company’s stock worth $3,811,000 after buying an additional 3,338,580 shares during the period. FMR LLC boosted its holdings in OptiNose by 3.2% in the third quarter. FMR LLC now owns 16,541,849 shares of the company’s stock valued at $11,083,000 after acquiring an additional 518,610 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in OptiNose by 5.3% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,075,638 shares of the company’s stock valued at $2,061,000 after acquiring an additional 155,329 shares during the period. 85.60% of the stock is owned by institutional investors and hedge funds.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.